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A B S T R A C T
Purpose: Antiepileptic drugs may affect the endocrine system. We investigated the effects of valproic
acid and topiramate on the levels of insulin, c-peptide and adipocytokines in pre-pubertal patients with
idiopathic partial and generalized epilepsy.
Methods: Forty-one children with epilepsy were included. The patients were divided into two groups
(valproic acid; n = 21, topiramate; n = 20). The weight, height, body mass index and homeostasis model
assessment of insulin resistance (HOMA-IR) were recorded and insulin, c-peptide, leptin, neuropeptide
Y, adiponectin, visfatin and resistin levels were determined at 0, 6 and 12 months of therapy.
Results: In the valproate group, weight and height increased signiﬁcantly. Seven of 21 patients were
overweight at the end of one year. Leptin was higher in the overweight subgroup. Although insulin and
HOMA-IR increased (p < 0.05), none of the patients showed hyperinsulinism or IR. Resistin had decreased
at the 6th and 12th months (p < 0.05). In the topiramate group, some statistically nonsigniﬁcant changes
were demonstrated.
Conclusion: The mechanisms behind valproate and topiramate-related weight control are still unclear,
especially in children. Valproate and topiramate affect the weight, BMI, and insulin, leptin and
adipocytokine levels in prepubertal children. We suggest that further studies including more patients
with a long follow-up period are necessary to draw a ﬁrm conclusion regarding an association between
the treatment with these drugs and the levels of leptin, insulin and adipocytokines.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is among the common chronic illnesses of childhood.
Anticonvulsant drugs are used for its long-term treatment. This
therapy may be associated with several metabolic abnormalities.1
Valproate is a broad-spectrum antiepileptic drug used effectively
in both partial and generalized seizures.2 Topiramate is a new
generation antiepileptic drug. In mid 2005 it was approved as
monotherapy in adults and children over 2 years.3,4 Although* Corresponding author. Current address: Turgut Ozal University, Faculty of
Medicine, Department of Child Neurology, Alparslan Turkes Caddesi, No: 57 Emek,
Ankara, Turkey. Tel.: +90 312 2035151; mobile: +90 533 654 8654.
E-mail addresses: mjgsonmez@yahoo.com, fmaynaci@dr.com (F.M. Sonmez).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.07.007many endocrinologic side effects have been reported with
valproate such as polycystic ovaries and hyperadrogenism the
most striking seem to be weight gain for valproate and weight loss
for topiramate.5
It was demonstrated in several studies that valproate is
associated with weight gain in approximately half of the patients
among both males and females.5–7 Although several mechanisms
have been implicated, those underlying valproate-related weight
gain remain unknown.8,9 The roles of hyperinsulinemia and insulin
resistance (IR) as well as of leptin, ghrelin and neuropeptide Y levels
have been investigated in patients with epilepsy who gained weight,
primarily in adults. However, studies including children with
epilepsy have been limited and the results appear controversial.10,11
It was shown that topiramate is effective in the treatment of
eating disorders and may cause energy expenditure in rats, but thevier Ltd. All rights reserved.
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investigating the mechanisms of topiramate in weight control are
limited. Although some of the study results have shown the role of
decreased leptin levels, increased adiponectin levels and increased
insulin sensitivity, the mechanisms behind the topiramate-related
weight loss are still unknown.14,15 The purpose of this study was to
evaluate possible changes in insulin, c-peptide, leptin, neuropep-
tide Y, adiponectin, visfatin and resistin levels during valproate or
topiramate therapies and their role in the weight status of children
with epilepsy.
2. Methods and materials
This study was carried out in the Department of Pediatric
Neurology with the approval of the Hospital Ethics Committee, and
was supported by the University Scientiﬁc Research Found.
Epilepsy type was classiﬁed according to the recommendations
of the International League Against Epilepsy. Written informed
parental consent was obtained from all participating subjects.16
2.1. Subjects
During the period July 2007–July 2008, 46 prepubertal patients
(ages range between 6 and 12 years; mean age: 8.3  1.7 years) with
a history of new-onset seizure and who were diagnosed as idiopathic
generalized or partial epilepsy were included in this study. The study
was completed with 41 of the 46 enrolled patients aged between 6 and
12 years. The study group consisted of 17 females (mean age: 8.7  0.5
years) and 24 males (mean age: 8.0  0.3 years). The epilepsy diagnosis
was based on history, neurologic examination, electroencephalography
(EEG), and magnetic resonance imaging (MRI). Patients with symptoms
and signs of illnesses other than epilepsy (e.g. endocrine, metabolic,
hepatic, or renal diseases), a history of status epilepticus, previous use
of any antiepileptic drugs, or previous use of drugs affecting calorie
intake were not included in the study. All patients had a normal
neurologic examination and normal cranial MRI ﬁndings.
The patients were divided into two groups according to their
drug therapy. Group 1 consisted of 24 patients, mean age 8.0  1.6
years, who received sodium valproate, 20 mg/kg/day, twice Daily, and
group 2 consisted of 22 patients, mean age 8.6  1.7 years, who
received topiramate 3 mg/kg/day, twice daily.
2.2. Methods
All patients were clinically examined and interviewed by the
ﬁrst author. Weight and height were measured and weight z score
and body mass index (BMI; as weight [in kilograms] divided by
height [in meters] squared) were calculated before the initiation of
the therapy and at the 6th and 12th months of therapy. All patients
with a BMI between the 85th and 95th percentiles for age and
gender were classiﬁed as overweight and those above the 95th
percentile for age and gender as obese. Pubertal development was
assessed according to Tanner stages and Tanner I patients were
included in the study.17
Blood samples were obtained at 8 a.m. after an overnight fast
for the analysis of serum insulin, c-peptide, leptin, neuropeptide Y,
adiponectin, visfatin, resistin and valproate concentrations. The
analyses were done before the initiation of therapy and at the 6th
and 12th months of the therapy. Topiramate concentrations could
not be measured. Plasma glucose concentrations were also
measured and the fasting serum glucose to insulin (G0/I0) ratio
was calculated. IR was estimated using the Homeostasis Model
Assessment of Insulin Resistance (HOMA-IR, fasting insulin x
fasting glucose/22.5).18 IR is deﬁned as HOMA-IR levels 3.16
according to the following equation: insulin (uIU/ml)  [glucose
(mg/dl)  0.055/22.5].2.3. Assays
Serum samples were frozen at 70 8C until analyzed. Serum
glucose concentrations were measured by Roche Modular Auto-
analyzer using commercial Roche diagnostic kits by enzymatic
calorimetric method.
The concentrations of insulin and c-peptide were analyzed with
chemiluminescence immunometric assay using a DPC-Immulite
2000 autoanalyzer. Leptin concentrations were analyzed with an
enzyme-ampliﬁed sensitivity immunoassay using kits from
BioSource Co. Neuropeptide Y and visfatin concentrations were
analyzed with a competitive enzyme immunoassay by using kits
from Phoenix Pharmaceuticals Co. Adiponectin and resistin
concentrations were analyzed with an enzyme-linked immuno-
sorbent assay using kits from Linco Research Co.
2.4. Statistical analysis
Statistical analyses were performed using the Statistical
Package for The Social Sciences software (SPSS 13.0.1 serial
number: 9069728). The chi-square test was used to compare
qualitative datas. In each group, the conformity of the measured
values to normal distribution was analyzed using Kolmogorov–
Smirnov test. Variation during the period for the data that
conformed to normal distribution was analyzed by repeated
measures ANOVA (post hoc by paired t test), and the data showing
skewed distribution were analyzed using Friedman test (post hoc
by Wilcoxon test) in each group. When comparing the two groups,
the data conforming to normal distribution were analyzed using
Student t test and data showing skewed distribution by Mann–
Whitney-U test, and correlations were analyzed by Pearson’s test.
A value of p < 0.05 was determined as statistically signiﬁcant.
3. Results
The study was completed with 41 of the 46 enrolled patients.
Five patients (3 from group 1 and 2 from group 2) dropped out of
the study because of uncontrolled seizures with monotherapy and
were treated at another center. Thus, evaluations were made based
on the results of 41 patients (17 females, 24 males) aged between 6
and 12 years. The mean age of the patients was 8.3  1.7 years.
Patients were divided into two groups according to their drug
therapy. Group 1 (sodium valproate) consisted of 21 patients (10
females, 11 males; mean age 8.0  1.6 years), and group 2
(topiramate) consisted of 20 patients (7 females, 13 males; mean
age: 8.5  1.8 years). There was no statistically signiﬁcant difference
between the two patient groups with respect to the mean age.
Epilepsy types were generalized in 9 patients (7 in group 1, 2 in
group 2) and partial seizures in 32 patients (14 in group 1, 18 in
group 2). The most common seizure types were complex partial in
21 patients (51.5%) and simple partial in 11 patients (27%)
(Table 1). The most common EEG ﬁnding was focal epileptiform
activity (58.5%) (Table 1). The rate of seizure control was similar
between the two groups.
In the valproate-treated group weight and height increased
signiﬁcantly both at the 6th and 12th months (p < 0.0005). BMI
increased signiﬁcantly at the 12th month compared with the
values at the 6th month of the therapy (p < 0.05) (Table 2). None of
the patients had become obese during the one-year-follow-up.
Although only 1 patient (4.7%) was overweight at the initiation of
the therapy, 4 patients at the 6th month (19%) and 7 patients at the
12th month (33%) had become overweight. When overweight and
non-overweight patients were compared, leptin levels were found
to be higher in the overweight group (p = 0.03). There were no
differences in the other laboratory parameters between the
overweight and non-overweight groups (Table 3).
Table 4
Anthropometric and laboratory data in patients treated with topiramate.
Parameters Initiation
Mean  SD
6th month
Mean  SD
12th month
Mean  SD
Weight (kg) 29.6  8.6 30.5  8.9 31.5  8.4
Height (cm) 127.8  12.5 128.4  11.9a 130.7  11.9
BMI (kg/m2) 17.8  2.5 17.4  2.5 17.4  2.3
Glucose (mg/dl) 84.3  6.6 84.7  5.2 82.1  8.6
G0/I0 25.5  13.7 23.9  13.4 26.3  12.6
HOMA-IR 0.9  0.5 1.1  0.8 0.8  0.7
Insulin (uIU/ml) 4.7  2.6 5.3  4.0 4.4  3.2
C-peptide (ng/ml) 1.1  0.5 1.2  0.6 0.9  0.5
Leptin (ng/ml) 3.4  3.0 2.6  2.6 2.4  2.1
Resistin (ng/ml) 9.7  3.6 10.3  3.4 8.9  3.6
Visfatin (ng/ml) 9.5  8.3 7.8  1.1 8.8  5.6
Neuropeptide Y (ng/ml) 0.9  0.8 0.6  0.4 0.7  0.5
Adiponectin (ng/ml) 13,687.8 
7028.4
14,417.2  5991.8 16,594.1 
8963.4
BMI: body mass index, G0/I0: fasting glucose/fasting insulin ratio.
HOMA-IR: homeostasis model assessment of insulin resistance.
a Comparison of 0 and 6 months: p < 0.001.
Table 1
Seizure type and EEG ﬁndings of the patients.
Seizure type n % EEG ﬁndings n %
Simple partial 11 27 Epileptiform activity
Complex partial 21 51.5 Focal 24 58.5
GTC 3 7 Generalized 6 14.6
Tonic 1 2.5 Paroxysmal abnormality
Clonic 3 7 Focal 6 14.6
Absance 2 5 Generalized 3 7.3
Normal 2 5
Total 41 100 Total 41 100
GTC, generalized tonic-clonic.
Table 3
The comparison of BMI and laboratory data among overweight and non overweight
patients in VPA treated group.
Overweight
(n = 7)
Non-overweight
(n = 14)
p
Mean  SD Mean  SD
BMI (kg/m2) 33.7  8.2 16.8  1.4 0.001a
G0/I0 21.4  9.7 29.6  13.4 0.16
HOMA-IR 1.1  0.6 0.7  0.6 0.28
Glucose (mg/dl) 78.3  5.1 80.2  6.0 0.48
I˙nsulin (uIU/ml) 5.6  3.2 3.8  2.9 0.20
C-peptide (ng/ml) 1.1  0.5 0.9  0.6 0.81
Leptin (ng/ml) 2.9  1.6 1.8  0.7 0.03b
Resistin (ng/ml) 8.3  4.3 7.2  2.0 0.56
Visfatin (ng/ml) 11.1  6.1 8.1  0.9 0.24
Neuropeptide Y (ng/ml) 0.5  0.2 0.7  0.3 0.23
Adiponectin (ng/ml) 15,151.4  4457.9 13,719.4  5656.8 0.57
BMI: body mass index, G0/I0: Fasting glucose/fasting insulin ratio, HOMA-IR:
Homeostasis model assessment of insulin resistance.
a p < 0.001.
b p < 0.05.
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and the G0/I0 ratio did not differ at 0, 6 and 12 months of therapy.
Although insulin levels and HOMA-IR increased during the follow-
up (p = 0.038 and p = 0.036), none of the patients showed
hyperinsulinism or IR. Resistin levels decreased signiﬁcantly at
the 6th and 12th months of therapy when compared to the levels at
the initiation of the therapy (p = 0.001), but there was no
correlation between resistin levels and BMI. There was no
signiﬁcant difference in c-peptide, visfatin and neuropeptide Y
levels during the follow-up (Table 4).
In the topiramate-treated group there was no difference in
weight, height, BMI, fasting glucose concentrations, HOMA-IR, c-
peptide, visfatin, and neuropeptide Y levels. Although the
participating children did not lose weight during topiramate
therapy, they also did not gain weight. It can thus be speculated
that the absence of a weight gain despite their being in a period of
growth may be the result of the anorectic effect of topiramate.
Insulin levels tended to increase at the 6th month of the therapy,
but this increase was not signiﬁcant. Resistin levels increased at
the 6th month but decreased at the 12th month, leptin showed a
decrease and adiponectin showed an increase at the 6th and 12th
months of therapy, but none of these results was statistically
signiﬁcant (Table 4).
There were no statistically signiﬁcant differences in insulin, c-
peptide, leptin, or other adipocytokines between male and female
patients in either group (Table 5).Table 2
Anthropometric and laboratory data in patients treated with valproate.
Parameters Initiation
Mean  SD
6th month
Mean  SD
12th month
Mean  SD
Weight (kg) 26.3  6.8 29.0  6.7a 30.7  6.7b,c
Height (cm) 125.0  8.7 128.6 9.9a 131.3  9.9b,c
BMI (kg/m2) 16.6  2.5 17.4  1.8d 17.6  1.7e
Glucose (mg/dl) 80.8  5.2 81.1  7.9 79.6  5.7
G0/I0 30.9  12.4 31.8  12.5 26.9  12.7
HOMA-IR 0.6  0.3 0.6  0.4 0.8  0.6f
Insulin (uIU/ml) 3.3  1.8 3.3  2.0 4.4  3.1f
C-peptide (ng/ml) 1.1  0.5 1.0  0.5 1.0  0.6
Leptin (ng/ml) 2.1  1.6 2.3  1.7 2.2  1.2
Resistin (ng/ml) 12.9  8.1 8.5  3.0 7.6  2.9c
Visfatin (ng/ml) 8.1  2.1 8.6  3.0 9.1  3.7
Neuropeptide Y (ng/ml) 0.8  0.3 0.6  0.3 0.6  0.3
Adiponectin (ng/ml) 13,086.6 
3680.9
13,451.7 
6015.3
14,196.7  5219.2
BMI, body mass index.
G0/I0: fasting glucose/fasting insulin ratio.
HOMA-IR: homeostasis model assesment of insulin resistance.
a Comparison of 0 and 6 month: p < 0.001.
b Comparison of 0 and 12 months: p < 0.001.
c Comparison of 6 and 12 months: p < 0.001.
d Comparison of 0 and 6 months: p < 0.05.
e Comparison of 0 and 12 month: p < 0.05.
f Comparison of 6 and 12 months: p < 0.05.4. Discussion
Weight gain is one of the most common adverse effects of
valproate. Although several mechanisms have been suggested, the
precise mechanisms underlying the valproate-related weight gain
remains unclear. Conceivable pathophyssiological mechanisms are
(1) dysregulation of the hypothalamic system with valproate
therapy; (2) valproate-induced hyperinsulinemia leading to IR, (3)
valproate-induced hyperleptinemia leading to leptin resistance; and
(4) possible interaction between valproate and adiponectin and
inﬂuence of genetic factors on body weight during valproic acid
therapy.8,9,20
Excessive weight gain can lead to worsened treatment
compliance. Several studies reported that valproate treatment
was related with excessive weight gain in children.21,22 In a one-
year prospective study, Verrotti et al.23 reported the obesity rates
as 35% in 20 prepubertal girls with epilepsy. In the same study the
participants were divided into two subgroups as overweight and
not overweight, and hyperinsulinemia and IR were shown in the
overweight group. In our study none of the valproate-treated
patients gained excessive weight or became obese, but 7 of the 21
patients (33%) had become overweight after one year of follow-up.
Because the patients in our study were prepubertal children, the
increase in weight and height can be accepted as usual. As BMI
reﬂects body fat, the increase in the BMI could be accepted as an
indicator of valproate-related weight gain.
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gain are differences in the serum fasting glucose and insulin levels.
The tendency of glucose levels to decrease is one such difference.24
Valproate itself is a derivative of fatty acids. The increase in the
long-chain fatty acids increases insulin production, and decreases
serum glucose concentrations.25 On the other hand valproate
inhibits b-oxidation of fatty acids. In our study, valproate-treated
patients showed neither a decrease in glucose levels nor a
correlation between insulin and glucose levels. These ﬁndings
indicate that there are additional factors. While serum insulin
levels reﬂects the hepatic metabolism,19 the increase in insulin
found in our study is thought to be due to the inhibition of hepatic
insulin metabolism by valproate.
Leptin is a product of the obese gene and is considered to be a
signal factor that regulates body weight and energy expenditure.
Obesity is associated with higher leptin levels.26Several studies have
shown an increase in leptin levels in obese compared with the non-
obese patients.19,27 In our study, the reason for the lack of an increase
in leptin levels might be attributed to the lack of obesity. However,
when we divided the patients into groups of overweight and not
overweight, the overweight group showed a signiﬁcant increase in
leptin levels. While these results suggested that valproate was not
interacting only with leptin in appetite and energy control, they did
not show that its effects were independent of leptin.
Leptin regulates body weight through neuropeptide Y, which
stimulates food intake and decreases energy expenditure. Neuro-
peptide regulates appetite via both central and peripheral
mechanisms.28 In a six-month follow-up study, Aydin et al.10
showed an increase in BMI, insulin, and neuropeptide Y levels at
the 3rd month of the valproate treatment. This increase was
thought to also be due to the serum insulin and leptin levels or
valproate-induced central and peripheral mechanisms. In our
study, there was no difference in neuropeptide Y levels during the
follow-up, and the lack of obesity could be a reason. Cansu et al.,11
suggested that increased serum leptin, neuropeptid Y and galanin
levels play an important role in valproate associated weight gain in
children.Adiponectin is an adipocyte-derived protein that plays a
major role in insulin sensitivity and regulation of glucose
homeostasis. Adiponectin levels are negatively correlated with
BMI, IR and cardiac events.29,30 In a study in children, Rauchen-
zauner et al.,31 demonstrated a similar result. It was known that
valproate-related weight gain is associated not only with elevated
insulin and leptin levels but also decreased adiponectin levels;
however, the underlying mechanisms remain unknown. In our
study, no difference in adiponectin levels was demonstrated
during the follow-up. When the negative correlation between
adiponectin levels and visceral fat is considered, the reason for the
lack of a difference in adiponectin levels may be the fact that none
of our patients developed obesity.
Visfatin is deﬁned as a protein that mimics insulin action and
activates intracellular signaling cascade for insulin. Haider et al.,32
suggested that high serum visfatin concentrations could be an
independent factor in the development of metabolic syndrome and
cause impaired glucose tolerance in obese children. However,
Rauchenzauner et al.,31 did not show a difference in visfatin
concentrations among obese and non-obese valproate-treated
children.30 The results of the prior study are thought to be
acceptable because none of the patients had visceral fat
accumulation and no difference in glucose concentrations was
seen. In our study, there was no difference in visfatin concentra-
tions, and the underlying reasons may be the same.
Resistin impaires insulin-stimulated glucose uptake, increases
hepatic glucose production, impairs glucose tolerance, and leads to
IR. Serum resistin levels increase in obesity but are positively
correlated with visceral fat instead of BMI.33 The results of resistin
and energy balance-associated human studies are controversial
F.M. Sonmez et al. / Seizure 22 (2013) 856–861860and the number of studies done with children using antiepileptic
drugs to clarify the mechanisms behind weight gain remains
limited. Tomoum et al.,34 found no difference between resistin
levels in valproate-treated children and reported that none of the
patients developed obesity. In our study, resistin showed an
increase at the 12th month when compared to levels at the
initiation of therapy. We could not explain this contradictory
result. As there are only a limited number of studies evaluating the
interaction of valproate treatment, weight gain and resistin levels,
more studies are needed to clarify the underlying mechanisms.
Topiramate is a new-generation antiepileptic drug that affects
body weight negatively.1,13,35 It was shown in some animal studies
that topiramate administration causes weight loss.36,37 Topira-
mate inhibits white adipose tissue depots and enhances regulatory
thermogenesis through its effect on lipoprotein lipase (LPL)
activity in brown adipose tissue. It stimulates LPL activity in
skeletal muscles and hence promotes substrate oxidation.35 LPL
activity in white fat tissue leads to a decrease in fat accumulation
and decreases blood glucose and triglyceride levels.38 Wilding
et al.39 showed weight loss and improved blood pressure and
glucose tolerance in obese patients after one year of follow-up in a
clinical series of 1289 patients with epilepsy. Ben-Menachem
et al.,40 reported body fat and weight loss within the 3rd month of
the topiramate therapy, and they suggested that decreased calorie
intake was effective in weight loss in the early stages of therapy. As
weight loss increased, a decrease in leptin levels and an
improvement in glucose, insulin and total cholesterol levels were
seen in the same study. York et al.,41 showed that topiramate
suddenly decreased food intake and increased the metabolic rate.
In the same study hypothalamic neuropeptide Y was shown to be
increased, leptin remained unaffected and leptin increased in the
adipose tissue. However, Theisen et al.,42 could not show a
relationship between topiramate-associated weight loss and leptin
levels in their prospective study. Li et al.,14 conducted a study
including 18 topiramate-treated children with epilepsy aged 6.8
years, and showed a decrease in BMI (the ﬁrst study in childhood
with topiramate). In that study, there was no difference between
leptin levels before and after the treatment, but adiponectin levels
were found to be increased, and the leptin/adiponectin ratio was
found to be decreased. These results suggested that the increase in
adiponectin levels during topiramate therapy might be an
important factor in topiramate-related weight loss.
The underlying mechanisms of topiramate-related weight loss
remain unknown. In our study, the decrease in leptin and increase in
adiponectin levels seen at the 6th and 12th months of the topiramate
treatment (though failing to reach a statistical signiﬁcance) and the
stability in BMI of the growing children (although no signiﬁcant
decrease in BMI was seen) might suggest that these changes could be
related to topiramate-associated weight loss. There was no
difference in the other parameters. We also were unable to describe
any difference in the leptin/adiponectin-ratio between the two
groups.
In conclusion, the mechanisms behind valproate, and topir-
amate-related weight control are still unclear, especially in children.
Valproate and topiramate affect the weight, BMI, and insulin and
leptin levels in prepubertal children. We suggest that further studies
including more patients with a long follow-up period are necessary
to draw a ﬁrm conclusion regarding an association between the
treatment with these antiepileptic drugs and the levels of leptin,
insulin, adiponectin, visfatin, neuropeptide-Y, and resistin.
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